



EUROPEAN COMMISSION

Health and Food Safety Directorate General

sante.g.3(2024)3705262

## **Standing Committee on Veterinary Medicinal Products**

**24 April 2024**

**CIRCABC Link:** [https://circabc.europa.eu/ui/group/a2ba6dd7-f812-406a-8b1c-2aaf25ec4277/library/02cb8ef5-3977-4a88-ae6c-62023bf9c8b0?p=1&n=10&sort=modified\\_DESC](https://circabc.europa.eu/ui/group/a2ba6dd7-f812-406a-8b1c-2aaf25ec4277/library/02cb8ef5-3977-4a88-ae6c-62023bf9c8b0?p=1&n=10&sort=modified_DESC)

### **SUMMARY REPORT**

The Chair opened the meeting by reminding participants about the confidentiality of the documents for the meeting and of the discussions in the meeting. The agenda of the meeting was adopted.

#### **A.01 Discussion on a draft Implementing Regulation on a list of antimicrobials which shall not be used in accordance with Articles 112 and 113 of Regulation (EU) 2019/6 or which shall only be used in accordance with these articles subject to certain conditions (under Article 107(6))**

The Commission presented an updated version of a working document, which took into account input provided by the Member States prior to the meeting.

Members States welcomed the updated version of the working document.

The Commission and the European Medicines Agency provided clarifications on technical points raised by some Member States. The Commission informed the Committee about the next procedural steps.

#### **A.02 Exchange of views on the development of a working document on measures on GMP for veterinary medicinal products under Article 93(2) of Regulation (EU) 2019/6**

The Commission presented a working document on the proposed approach to include the GMP requirements in the future implementing act/s in view of the legal basis provided for in the VMP Regulation.

The Member States were requested to provide their comments on the proposed approach.

#### **M.01 AoB**

The Commission informed the Standing Committee of the upcoming consultation (through the written procedure) on a Commission decision suspending the marketing authorisation and recalling of batches for a centrally authorised product and on a Commission decision granting a marketing authorisation under exceptional circumstances. In both cases, the consultation period of the Committee will be reduced to 5 days.